Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study

Gil-Prieto, Ruth; Pascual-García, Raquel; Walter, Stefan; Álvaro-Meca, Alejandro; Miguel, Ángel Gil de

doi:10.1080/21645515.2016.1143577

Cited by 33 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, AIDS, lung transplantation, asplenia, and aplastic anemia seem to be less frequent at admission and to represent distinct clinical entities. Findings of previous studies seem to be in line with our results, with AIDS patients considered as a distinct patient population and with very few observational studies available on asplenia and aplastic anemia [21,[27][28][29][30][31] In agreement with previous reports, S. pneumoniae is the leading microorganism in both immunocompromised and immunocompetent groups [32,33]. Among pathogens covered by standard CAP therapy, only P. aeruginosa was more frequently isolated in immunocompromised compared with immunocompetent patients.…”

Section: Discussionsupporting

confidence: 92%

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Pasquale

Sotgiu

Gramegna

et al. 2018

Clinical Infectious Diseases

142

View full text Add to dashboard Cite

Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor.Results. At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001).Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

show abstract

Section: Discussionsupporting

confidence: 92%

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Pasquale

Sotgiu

Gramegna

et al. 2018

Clinical Infectious Diseases

142

View full text Add to dashboard Cite

show abstract

“…For hospitalised pneumococcal CAP, the highest incidence (421 per 100,000 population) was reported in Spain in patients aged ≥85 years [96] (Table 2). Data on hospitalised IPD or invasive pneumococcal CAP were only available from Spain, however, with the incidence ranging from 7 per 100,000 population in patients of all ages [74] to 45 per 100,000 population in patients aged > 64 years [70] ( Table 2).…”

Section: Burden Of Diseasementioning

confidence: 99%

“…[5,[26][27][28][29]31,[34][35][36]39,40,44,46,51,[53][54][55][56][57]60,64,67,[70][71][72][74][75][76][77]80,88,89,[91][92][93]96].…”

mentioning

confidence: 99%

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Torres

Blasi

Chalmers

et al. 2018

Respiratory Medicine

107

View full text Add to dashboard Cite

show abstract

“…(22) In a Spanish study, patients aged 18-64 years with liver disease had a higher index of hospitalization for PP (OR: 56.3, 95% CI: 49.1-64.6) than patients aged ≥ 65 years (OR: 15.0, 95% CI: 13.1-17.2). (23) Chronic renal disease is an important cause of mortality worldwide, and the incidence of pneumonia in dialysis patients is 27.9/100 persons/year, with a 1-year survival rate of 0.51. (24) In our study, chronic renal failure was more prevalent in the population aged < 65 years (p < 0.01), but there was no impact of this condition on mortality (p = 0.15).…”

Section: Discussionmentioning

confidence: 99%

Mortalidade e custos da pneumonia pneumocócica em adultos: um estudo transversal

et al. 2019

View full text Add to dashboard Cite

RESUMO Objetivo A pneumonia pneumocócica é uma causa significativa de morbimortalidade entre adultos. Desta maneira, o objetivo principal deste estudo foi avaliar a mortalidade intra-hospitalar e os custos relacionados à doença adquirida em adultos. Métodos Este estudo transversal utilizou prontuários de pacientes adultos com pneumonia pneumocócica internados em um hospital universitário no Brasil, de outubro de 2009 a abril de 2017. Todos os pacientes com idade ≥ 18 anos e diagnosticados com pneumonia pneumocócica foram incluídos. Dados como os fatores de risco, a internação em unidade de terapia intensiva, o tempo de internação, a mortalidade hospitalar e os custos diretos e indiretos foram analisados. Resultados No total, 186 pacientes foram selecionados. A taxa média de mortalidade intra-hospitalar foi de 18% para adultos com idade < 65 anos e 23% para os idosos (≥ 65 anos). A pneumonia pneumocócica bacterêmica acometeu 20% dos pacientes em ambos os grupos, principalmente por doença respiratória crônica (OR ajustada: 3,07; IC95%: 1,23‐7,65; p < 0,01). Após levantamento das internações ocorridas no período de sete anos de tratamento, verificou-se que os custos diretos e indiretos totais anuais foram de US$ 28.188 para adultos < 65 anos (US$ 1.746 per capita) e US$ 16.350 para os idosos (US$ 2.119 per capita). Conclusão A pneumonia pneumocócica continua sendo uma importante causa de morbimortalidade entre adultos, afetando significativamente os custos diretos e indiretos. Esses resultados sugerem a necessidade de estratégias de prevenção para todos os adultos, especialmente para pacientes com doenças respiratórias crônicas.

show abstract

Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study

Cited by 33 publications

References 21 publications

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Mortalidade e custos da pneumonia pneumocócica em adultos: um estudo transversal

Contact Info

Product

Resources

About